TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01806779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Description: All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Description: All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
Study: NCT06491758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastroelectric Stimulator (GES)
Description: This procedure is where patients with GES already implanted will have EKG readings and blood draws taken for baseline, experimental (stimulator turned off) and Recovery (Stimulator turned on) Blood Draws are for obtaining levels of Insulin, C-Peptides and Glucose levels to track changes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastroelectric Stimulator (GES)
Description: This procedure is where patients with GES already implanted will have EKG readings and blood draws taken for baseline, experimental (stimulator turned off) and Recovery (Stimulator turned on) Blood Draws are for obtaining levels of Insulin, C-Peptides and Glucose levels to track changes.
Study: NCT00861744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's investigational vaccine 209762
Description: Subcutaneous injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's investigational vaccine 209762
Description: Subcutaneous injection, one dose
Study: NCT06491758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaVNS (Transcutaneous Auricular Vagal Nerve Stimulation) Device
Description: • Two MRI compatible electrodes will be placed in the auricle of the left ear, fixed by a plastic armature that wraps around the ear. The leads from the electrodes are connected to a stimulator.• Two ECG electrodes are placed on both sides of the neck overlying the area near the carotid artery where the vagus nerve is superficial. This is to measure the vagal action potentials in the neck.• Two ECG electrodes are placed one on each arm and one on the chest for measurement of the electrocardiogram.• Three ECG electrodes are placed on the abdomen in a line parallel to the longitudinal axis of the stomach to record the ECG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaVNS (Transcutaneous Auricular Vagal Nerve Stimulation) Device
Description: • Two MRI compatible electrodes will be placed in the auricle of the left ear, fixed by a plastic armature that wraps around the ear. The leads from the electrodes are connected to a stimulator.• Two ECG electrodes are placed on both sides of the neck overlying the area near the carotid artery where the vagus nerve is superficial. This is to measure the vagal action potentials in the neck.• Two ECG electrodes are placed one on each arm and one on the chest for measurement of the electrocardiogram.• Three ECG electrodes are placed on the abdomen in a line parallel to the longitudinal axis of the stomach to record the ECG
Study: NCT04897243

Intervention type: DRUG
Intervention: Biktarvy
Description: B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.

Intervention type: DRUG
Intervention: Biktarvy
Description: B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.
Study: NCT00861744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's investigational vaccine 209762
Description: Subcutaneous injection, one dose
Study: NCT04897243

Intervention type: BEHAVIORAL
Intervention: Patient Experience
Description: To capture and integrate the patient experience, this study will collect patient-reported experience measures, conduct qualitative interviews, and engage patients as well as providers.

Intervention type: BEHAVIORAL
Intervention: Patient Experience
Description: To capture and integrate the patient experience, this study will collect patient-reported experience measures, conduct qualitative interviews, and engage patients as well as providers.
Study: NCT00861744

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R® II (Merck and Co)
Description: Subcutaneous injection, one dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax®
Description: Subcutaneous injection, one dose
Study: NCT02137798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radio-frequency catheter ablation
Description: Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude \< o.5 mV) will also be ablated.
Study: NCT00861744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax®
Description: Subcutaneous injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax®
Description: Subcutaneous injection, one dose
Study: NCT02137798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio-frequency catheter ablation
Description: Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude \< o.5 mV) will also be ablated.
Study: NCT00861744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax®
Description: Subcutaneous injection, one dose
Study: NCT02030873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual simulation training
Description: Virtual simulation training in the Visible Ear Simulator.
Study: NCT00359476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
Study: NCT00861744

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®
Description: Intramuscular injection, one dose
Study: NCT04470427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT00861744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar®
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar®
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar®
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar®
Description: Intramuscular injection, one dose
Study: NCT04248439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L102
Description: CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
Study: NCT04470427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT03196141

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: StO2 and EndoPAT
Description: * StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~* The EndoPAT probe will be place on a finger on the same arm.~* Pulse oximeter probes will be connected to a finger on each hand.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: StO2 and EndoPAT
Description: * StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~* The EndoPAT probe will be place on a finger on the same arm.~* Pulse oximeter probes will be connected to a finger on each hand.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: StO2 and EndoPAT
Description: * StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~* The EndoPAT probe will be place on a finger on the same arm.~* Pulse oximeter probes will be connected to a finger on each hand.
Study: NCT02550795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of dexmedetomidine only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine and dexamethasone
Description: administration of dexmedetomidine and dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: administration of normal saline
Study: NCT02610010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Intensity-modulated radiotherapy
Study: NCT02595450

Intervention type: DRUG
Intervention: Erlotinib
Description: Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
Study: NCT00578305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was supplied as a sterile liquid for iv administration.
Study: NCT02610010

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: Intensity-modulated radiotherapy
Study: NCT01113242

Intervention type: OTHER
Intervention: Neuropsychological Assessment
Description: Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,...) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) \<16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.

Intervention type: OTHER
Intervention: Neuropsychological Assessment
Description: Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,...) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) \<16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.
Study: NCT02225587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevnar 13™
Description: Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
Study: NCT02225587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax™ 23
Description: Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pneumovax™ 23
Description: Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections are to be administered into the deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections are to be administered into the deltoid muscle of the upper arm.
Study: NCT04508816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab (CTX) or nimotuzumab (NTZ)
Description: The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.
Study: NCT01806129

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard practice related to reproductive heath
Description: Patients undergo usual standard practice related to reproductive health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training modules, algorithm, referral development
Description: Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
Study: NCT00578305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a sterile liquid in single-use vials for iv administration.
Study: NCT01676662

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Solace Bladder Control System
Description: Subjects may undergo treatment every 12 months until study completion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solace Bladder Control System
Description: Subjects may undergo treatment every 12 months until study completion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Solace Sham Treatment
Description: Sham procedure that resembles treatment with the Solace Bladder Control System
Study: NCT01796522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone 200 mg / day vaginally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nifedipine (60 mg / day orally)
Study: NCT04132219

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: eHealth Intervention
Description: Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
Study: NCT00578305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Study: NCT04132219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Intervention
Description: Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
Study: NCT00578305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid or folate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid or folate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid or folate
Study: NCT04265183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placing preformed metal crowns using Hall technique.
Description: Preformed metal crowns (3M™ ESPE™ STAINLESS STEEL CROWNS) were placed after using separation elastics (Dentalastics® separators, DENTAURUM). The crowns were cemented using is a self-curing, radiopaque, fluoride-releasing, resin-modified glass ionomer luting cement (Ketac™ Cem Plus Luting Cement, 3M™ ESPE™). The technique used to place the crowns was the Hall technique (technique without tooth preparation).
Study: NCT01534533

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one gelatine capsule containing starch per day, for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein group
Description: one gelatine capsule containing 20mg lutein per day, for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination group
Description: one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
Study: NCT02585765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 8 weeks of daily pioglitazone (30 mg/d).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks of daily placebo capsules.
Study: NCT03625128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18
Description: This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
Study: NCT03907215

Intervention type: DRUG
Group type: OTHER
Intervention: ACT541468
Description: 50 mg; film-coated tablet for oral use

Intervention type: DRUG
Group type: OTHER
Intervention: ACT541468
Description: 50 mg; film-coated tablet for oral use

Intervention type: DRUG
Group type: OTHER
Intervention: ACT541468 placebo
Description: film-coated tablet for oral use

Intervention type: DRUG
Group type: OTHER
Intervention: ACT541468 placebo
Description: film-coated tablet for oral use
Study: NCT01534533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal lutein control group
Description: subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
Study: NCT03895866

Intervention type: OTHER
Intervention: The participants were assigned to different groups according to the results of HPV detection.
Description: The participants were assigned to different groups according to the results of HPV detection

Intervention type: OTHER
Intervention: The participants were assigned to different groups according to the results of HPV detection.
Description: The participants were assigned to different groups according to the results of HPV detection
Study: NCT03907215

Intervention type: DRUG
Group type: OTHER
Intervention: Citalopram
Description: 20 mg; tablet tor oral use; for single- or repeated dosing
Study: NCT03588338

Intervention type: DRUG
Group type: OTHER
Intervention: Perfalgan
Description: For postoperative pain
Study: NCT02433652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant live attenuated trivalent dengue vaccine
Description: Contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10\^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10\^3.0 PFU of each component.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03588338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perfalgan
Description: For postoperative pain

Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: For postoperative nausea and vomiting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: For postoperative nausea and vomiting
Study: NCT02172547

Intervention type: DRUG
Intervention: Spiriva
Study: NCT00130364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus 1 % cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pimecrolimus vehicle cream (placebo)
Study: NCT00294658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thymectomy plus prednisone
Description: The thymectomy will be performed as soon as possible after randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone alone
Description: Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
Study: NCT03617302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Nitrate-containing
Description: Experimental
Study: NCT02433652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169 vaccine
Description: Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10\^3 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169 vaccine
Description: Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10\^3 PFU
Study: NCT03617302

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Nitrate-depleted
Description: Placebo
Study: NCT02481921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group medical visits
Description: Group clinics or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and/or medication management join to manage heart failure in addition to and in support of, the patient's regular individual clinic visits.